
1. int j parasitol drugs drug resist. 2013 aug 12;3:135-42. doi:
10.1016/j.ijpddr.2013.07.001. ecollection 2013 dec.

polymorphism dhfr/dhps genes, parasite density ex vivo response to
pyrimethamine plasmodium falciparum malaria parasites thies, senegal.

ndiaye d(1), dieye b(1), ndiaye yd(1), van tyne d(2), daniels r(2), bei ak(2),
mbaye a(1), valim c(2), lukens a(2), mboup s(1), ndir o(1), wirth df(2), volkman 
s(2).

author information: 
(1)faculty medicine pharmacy, university cheikh anta diop, dakar, po box
5005, dakar, senegal.
(2)department immunology infectious diseases, harvard school public
health, boston, 02115, usa.

resistance sulfadoxine-pyrimethamine (sp) plasmodium falciparum malaria
parasites associated mutations dihydrofolate reductase (dhfr) 
dihydropteroate synthase (dhps) genes, mutations spread resistance
worldwide. sp, used several years senegal, recommended for
intermittent preventive treatment malaria pregnancy (iptp) been
widely implemented since 2003 country. currently limited data on
sp resistance molecular marker genotyping, data pyrimethamine ex
vivo sensitivity senegal. molecular markers sp resistance pyrimethamine
ex vivo sensitivity investigated 416 parasite samples collected 
general population, thies region 2003 2011. prevalence
of n51i/c59r/s108n triple mutation dhfr increased 40% 2003 93% 
in 2011. furthermore, prevalence dhfr n51i/c59r/s108n dhps a437g
quadruple mutation increased, 20% 66% time frame, down
to 44% 2011. significant increase prevalence dhfr
triple mutation, well association dhfr genotypes and
pyrimethamine response. conversely, dhps mutations codons 436 437 
show consistent variation 2003 2011. findings suggest that
regular screening molecular markers antifolate resistance ex vivo drug
response monitoring incorporated ongoing vivo efficacy
monitoring areas iptp-sp implemented pyrimethamine and
sulfa drugs still widely administered general population.

doi: 10.1016/j.ijpddr.2013.07.001 
pmcid: pmc3862402
pmid: 24533303 

